Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PAVmedPAVMW 32 Debt-to-Equity is 0.43 as of Mar. 2026. GuruFocus rates PAVMW with a GF Score™ of 32/100. The stock has 6 warning signs investors should review. Among 706 Medical Devices & Instruments companies, PAVmed ranks worse than 65.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PAVmed's Debt-to-Equity or its related term are showing as below:
PAVMW'
s Debt-to-Equity Range Over the Past 10 Years
Min: -12.77 Med: -0.7 Max: 9.07
Current: 0.43
During the past 12 years, the highest Debt-to-Equity Ratio of PAVmed was 9.07. The lowest was -12.77. And the median was -0.70.
PAVMW's Debt-to-Equity is ranked worse than 65.44% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs PAVMW: 0.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PAVmed Debt-to-Equity Related Terms
PAVmed Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PAVmed's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAVMW vs BDMD, NSPR, TELA: Debt-to-Equity Comparison
For the Medical Devices subindustry, PAVmed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PAVmed Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PAVmed's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAVmed (PAVMW) has a Debt-to-Equity of 0.43 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PAVmed and its competitors. According to the industry distribution chart, PAVmed ranks #462 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 65.4%.
Is PAVmed's Debt-to-Equity too high?
PAVmed's current Debt-to-Equity is 0.43. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. PAVmed's value of 0.43 is 87% above this industry median. Based on the distribution chart, PAVmed ranks #462 out of 706 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PAVmed has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PAVmed's Debt-to-Equity compare to BDMD and NSPR?
According to the Medical Devices & Instruments industry distribution chart, PAVmed ranks #462 out of 706 companies for Debt-to-Equity. This places PAVmed in the lower half of its industry. The industry median Debt-to-Equity is 0.23. PAVmed's value of 0.43 is 87% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PAVmed's current Debt-to-Equity of 0.43 is 87% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PAVmed and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PAVmed's current Debt-to-Equity is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
PAVmed (PAVMW) has a current Debt-to-Equity of 0.43. The current Debt-to-Equity is 0.43 and 87% above the Medical Devices & Instruments industry median of 0.23. PAVmed's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PAVmed (PAVMW), the current Debt-to-Equity is 0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
32GF Score
Get the complete analysis for PAVMW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAVMW has been successfully added to your 
